BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24444539)

  • 1. Pioglitazone use and the risk of bladder cancer.
    Kuo HW; Tiao MM; Ho SC; Yang CY
    Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
    Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
    Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
    Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
    Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
    Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
    JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
    Fujimoto K; Hamamoto Y; Honjo S; Kawasaki Y; Mori K; Tatsuoka H; Matsuoka A; Wada Y; Ikeda H; Fujikawa J; Koshiyama H
    Diabetes Res Clin Pract; 2013 Feb; 99(2):e21-3. PubMed ID: 23228390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
    Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
    Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
    Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
    BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
    Azoulay L; Yin H; Filion KB; Assayag J; Majdan A; Pollak MN; Suissa S
    BMJ; 2012 May; 344():e3645. PubMed ID: 22653981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
    Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
    Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
    Han E; Jang SY; Kim G; Lee YH; Choe EY; Nam CM; Kang ES
    Medicine (Baltimore); 2016 Feb; 95(6):e2786. PubMed ID: 26871835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
    Tseng CH
    J Formos Med Assoc; 2012 Mar; 111(3):123-31. PubMed ID: 22423665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone and bladder cancer: a population-based study of Taiwanese.
    Tseng CH
    Diabetes Care; 2012 Feb; 35(2):278-80. PubMed ID: 22210574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone causing urinary bladder cancer? While waiting for the result of the debate, suggestions for physicians.
    Cagiltay E; Tuncel T; Yönem A; Ozdemir G
    Eur J Intern Med; 2013 Mar; 24(2):e21-2. PubMed ID: 23267737
    [No Abstract]   [Full Text] [Related]  

  • 14. Observational follow-up of the PROactive study: a 6-year update.
    Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
    Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
    Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
    Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
    Lewis JD; Habel L; Quesenberry C; Mamtani R; Peng T; Bilker WB; Hedderson M; Nessel L; Vaughn DJ; Strom BL; Ferrara A
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):636-45. PubMed ID: 24764283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone and bladder cancer: the pros and cons.
    Panikar V
    J Assoc Physicians India; 2012 Jan; 60():72-3. PubMed ID: 22715550
    [No Abstract]   [Full Text] [Related]  

  • 18. Pioglitazone use and risk of bladder cancer: population based cohort study.
    Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
    BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
    Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
    J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
    Lee MY; Hsiao PJ; Yang YH; Lin KD; Shin SJ
    PLoS One; 2014; 9(1):e85479. PubMed ID: 24427312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.